Related Experiment Video
Updated: Oct 14, 2025
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
An empirical pipeline for personalized diagnosis of Lafora disease mutations
M Kathryn Brewer1,2, Maria Machio-Castello3, Rosa Viana4
1Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
Insights
Lafora disease, a fatal dementia, stems from mutations in EPM2A or EPM2B genes. A new pipeline rapidly classifies EPM2A mutations, aiding Lafora disease patient treatment.
Area of Science:
- Neurogenetics
- Biochemistry
Background:
- Lafora disease (LD) is a fatal, progressive myoclonic epilepsy in children.
- Mutations in EPM2A (laforin) or EPM2B (malin) cause LD.
- EPM2A variants can lead to late-onset or slower LD progression.
Purpose of the Study:
- To establish a pipeline for characterizing laforin missense mutations in vitro.
- To functionally classify EPM2A mutations and correlate them with clinical outcomes.
- To provide genetic information for guiding Lafora disease patient treatment.
Main Methods:
- Developed an empirical pipeline for in vitro functional characterization.
- Employed complementary biochemical approaches to analyze mutations.
- Analyzed 26 laforin missense mutations.
Main Results:
- Identified distinct functional classes of laforin mutations.
- Correlated mutation classes with clinical outcomes, including disease progression.
- Demonstrated that mutations like F321C and G279C show attenuated defects and slow progression.
Conclusions:
- The developed pipeline enables rapid characterization and classification of EPM2A mutations.
- Functional classification aids in understanding genotype-phenotype correlations in Lafora disease.
- This genetic information can guide clinical management and treatment strategies for LD patients.
Abstract:
Lafora disease (LD) is a fatal childhood dementia characterized by progressive myoclonic epilepsy manifesting in the teenage years, rapid neurological decline, and death typically within ten years of onset. Mutations in either EPM2A, encoding the glycogen phosphatase laforin, or EPM2B, encoding the E3 ligase malin, cause LD. Whole exome sequencing has revealed many EPM2A variants associated with late-onset or slower disease progression. We established an empirical pipeline for characterizing the functional consequences of laforin missense mutations in vitro using complementary biochemical approaches. Analysis of 26 mutations revealed distinct functional classes associated with different outcomes that were supported by clinical cases. For example, F321C and G279C mutations have attenuated functional defects and are associated with slow progression. This pipeline enabled rapid characterization and classification of newly identified EPM2A mutations, providing clinicians and researchers genetic information to guide treatment of LD patients.
